Comparison of two clinical severity scoring systems in two multi-center, developing country rotavirus vaccine trials in Africa and Asia

Vaccine

Volumn 30, Issue SUPPL. 1, 2012, Pages

  Lewis, Kristen D C ^a   Dallas, Michael J ^b   Victor, John C ^a   Ciarlet, Max ^b,g   Mast, T Christopher ^b   Ji, Ming ^c   Armah, George ^d   Zaman, K ^e   Ferraro, Aimee ^f   Neuzil, Kathleen M ^a  

^a PATH   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c SAN DIEGO STATE UNIVERSITY   (United States)

^d University of Ghana   (Ghana)

^e INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^f WALDEN UNIVERSITY   (United States)

^g NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

Author keywords

Clark scoring system; Gastroenteritis; Rotavirus; Severity score; Vaccine efficacy; Vesikari scoring system

Indexed keywords

PLACEBO; ROTAVIRUS VACCINE;

AFRICA; ARTICLE; ASIA; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DEVELOPING COUNTRY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ROTAVIRUS; SCORING SYSTEM; VIRAL GASTROENTERITIS;

AFRICA; ASIA; CHILD, PRESCHOOL; DEVELOPING COUNTRIES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PLACEBOS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SEVERITY OF ILLNESS INDEX;

EID: 84859992762     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.126     Document Type: Article

References (28)

1. Parashar U.D., Hummelman E.G., Bresee J.S., Miller M.A., Glass R.I. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003, 9(May (5)):565-572.
2. Rotavirus surveillance-worldwide, 2009. MMWR Morb Mortal Wkly Rep 2011;60(April (16)):514-6.
3. UNICEF, World Health Organization Diarrhoea: why children are still dying and what can be done 2009, World Health Organization, Geneva.
4. Glass R.I., Parashar U.D., Bresee J.S., Turcios R., Fischer T.K., Widdowson MA, et al. Rotavirus vaccines: current prospects and future challenges. Lancet 2006, 368(July (9532)):323-332.
5. World Health Organization. Generic protocol for monitoring impact of rotavirus vaccination on gastroenteritis disease burden and viral strains. Geneva: World Health Organization; 2008 [Report No.: WHO/IVB/08.16].
6. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362(January (4)):289-298.
7. Zaman K., Anh D.D., Victor J.C., Shin S., Yunus M., Dallas M.J., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376(August (9741)):615-623.
8. Armah G.E., Sow S.O., Breiman R.F., Dallas M.J., Tapia M.D., Feikin D.R., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376(August (9741)):606-614.
9. Breiman R.F., Zaman K., Armah G.E., Sow S.S., Dang A.D., Victor J.C., et al. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine 2012, 30(Suppl. 1):A24-A29.
10. Meeting of the immunization Strategic Advisory Group of Experts, April 2009-conclusions and recommendations. Wkly Epidemiol Rec 2009;84(June (23)):220-36.
11. Steele A.D., Patel M., Parashar U.D., Victor J.C., Aguado T., Neuzil K.M. Rotavirus vaccines for infants in developing countries in Africa and Asia: considerations from a world health organization-sponsored consultation. J Infect Dis 2009, 200(November (Suppl. 1)):S63-S69.
12. World Health Organization. Global framework for immunization monitoring and surveillance. Geneva: World Health Organization; 2011 [Report No.: WHO/IVB/07.06].
13. WHO Expert Committee on Biological Standardization. WHO Expert Committee on Biological Standardization 56th Report: guidelines to assure the quality, safety and efficacy of live attenuated rotavirus vaccines (oral). Geneva: World Health Organization; 2007 [Report No.: 941].
14. de Palma O., Cruz L., Ramos H., de Baires A., Villatoro N., Pastor D., et al. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. BMJ 2010, 340:c2825.
15. Patel M., Pedreira C., De Oliveira L.H., Tate J., Orozco M., Mercado J., et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009, 301(June (21)):2243-2251.
16. Freedman S.B., Eltorky M., Gorelick M. Evaluation of a gastroenteritis severity score for use in outpatient settings. Pediatrics 2010, 125(June (6)):e1278-e1285.
17. Clark H.F., Borian F.E., Bell L.M., Modesto K., Gouvea V., Plotkin S.A. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. J Infect Dis 1988, 158(September (3)):570-587.
18. Clark H.F., Bernstein D.I., Dennehy P.H., Offit P., Pichichero M., Treanor J., et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr 2004, 144(February (2)):184-190.
19. Ruuska T., Vesikari T. A prospective study of acute diarrhoea in Finnish children from birth to 2 1/2 years of age. Acta Paediatr Scand 1991, 80(May (5)):500-507.
20. Ruuska T., Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990, 22(3):259-267.
21. World Health Organization. IMCI handbook: integrated management of childhood illness. Geneva: World Health Organization; 2005 [Report No.: WHO/FCH/CAH/00.12].
22. Georges-Courbot M.C., Monges J., Beraud-Cassel A.M., Gouandjika I., Georges A.J. Prospective longitudinal study of rotavirus infections in children from birth to two years of age in Central Africa. Ann Inst Pasteur Virol 1988, 139(October (4)):421-428.
23. Givon-Lavi N., Greenberg D., Dagan R. Comparison between two severity scoring scales commonly used in the evaluation of rotavirus gastroenteritis in children. Vaccine 2008, 26(October (46)):5798-5801.
24. Vesikari T., Clark H.F., Offit P.A., Dallas M.J., DiStefano D.J., Goveia M.G., et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine 2006, 24(May (22)):4821-4829.
25. Byrt T. How good is that agreement?. Epidemiology 1996, 7(September (5)):561.
26. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354(January (1)):23-33.
27. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354(January (1)):11-22.
28. Tapia M.D., Armah G.E., Breiman R.F., Dallas M.J., Lewis K.D.C., Sow S.S., et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine 2012, 30(Suppl. 1):A79-A85.